Business Context and Reporting Period
This Form 8-K is a current report filed by pSivida Corp. (not Eyepoint, Inc.) on April 26, 2010. The report addresses Item 9.01 regarding Financial Statements and Exhibits. The registrant is incorporated in Delaware with principal executive offices in Watertown, MA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the filing of an exhibit and does not contain a financial statement or performance summary.
Material Changes
No material financial changes or operational updates are detailed in the body of this filing. The primary disclosure is the submission of an exhibit related to a collaboration agreement.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors. The only notable item is the filing of an Amended and Restated Collaboration Agreement between pSivida, Inc. and Alimera Sciences, Inc., dated March 14, 2008. The text notes that certain provisions of this agreement have been omitted from the public filing because confidential treatment has been requested from the SEC.
Investor Verification Checklist
- Verify the identity of the registrant as pSivida Corp., distinct from Eyepoint, Inc.
- Review the full text of the Amended and Restated Collaboration Agreement with Alimera Sciences, Inc. (Exhibit 10.1) to understand the omitted confidential provisions.
- Confirm the status of the confidential treatment request with the SEC to determine if the omitted material has been made public.
- Check subsequent filings for any financial impact resulting from the collaboration agreement referenced in this exhibit.